Journal of Clinical Oncology | Efficacy and Safety Analysis of Zenocutuzumab in NRG1 Fusion-Positive Cholangiocarcinoma

This study provides a novel therapeutic strategy for cholangiocarcinoma patients targeting NRG1 fusion-driven tumors. It suggests that RNA sequencing should be prioritized in preclinical research to accurately identify such rare variants, thereby optimizing the target screening process for drug development.

 

Literature Overview

This article, titled "Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial," published in the Journal of Clinical Oncology, systematically explores the anti-tumor activity and safety of the bispecific antibody Zenocutuzumab in patients with advanced NRG1 fusion-positive cholangiocarcinoma. The results demonstrate that this therapy achieves significant objective response rates and durable disease control in patients who have failed prior treatments, offering new hope for this rare subtype lacking effective treatment options.

Background Knowledge

Cholangiocarcinoma is an aggressive malignancy with a poor prognosis, particularly in advanced stages, where traditional chemotherapy regimens have limited efficacy and high toxicity. NRG1 gene fusion, as a rare oncogenic driver, promotes tumor growth by activating HER2 and HER3 receptor dimerization and the downstream PI3K/AKT/mTOR signaling pathway. However, current detection of NRG1 fusion in cholangiocarcinoma faces significant bottlenecks; traditional DNA sequencing often misses these fusions due to large introns or diverse fusion partners, leading to many patients being denied precise targeted therapy. Addressing this pain point, this study utilized the high sensitivity of RNA sequencing in the eNRGy trial to screen for eligible patients, aiming to validate the clinical feasibility of blocking the HER2/HER3 signaling axis and filling the gap of approved targeted drugs for this molecular subtype.

 

 

Research Methods and Experiments

This study employed a single-arm, multi-center Phase II clinical trial design (the eNRGy trial), enrolling 22 patients with advanced cholangiocarcinoma confirmed by RNA sequencing to carry NRG1 fusions. Patients received intravenous infusions of Zenocutuzumab (750 mg) every two weeks. The core of the study was to evaluate the investigator-assessed objective response rate (ORR), supplemented by progression-free survival (PFS), overall survival (OS), and safety analyses. To verify the robustness of the results, the study also utilized blinded independent central review (BICR) for data verification and conducted an in-depth analysis of the correlation between dynamic changes in serum biomarkers (such as CA 19-9 and CEA) and tumor burden.

Key Conclusions and Perspectives

• Zenocutuzumab demonstrated significant anti-tumor activity in cholangiocarcinoma patients, with an investigator-assessed ORR of 36.8% and a median duration of response (DOR) of 7.4 months. This provides solid clinical data support for future combination therapy research targeting NRG1 fusion in drug development.
• The therapy exhibited a favorable safety profile, with most treatment-related adverse events being Grade 1-2, and no patients discontinuing due to adverse reactions. This suggests that clinical monitoring should focus on common symptoms such as diarrhea and fatigue, laying the foundation for future application in broader patient populations, including those with poorer performance status.
• The study confirmed that RNA sequencing is the gold standard for detecting NRG1 fusion, with a detection rate of 100% compared to only 28.6% for DNA sequencing. This finding directly guides the optimization of disease modeling and clinical screening strategies, emphasizing that transcriptomic analysis must be included when constructing molecular subtyping for cholangiocarcinoma.
• Even after disease progression, some patients with oligoprogression continued to benefit from ongoing treatment. This suggests that future research directions should further explore strategies combining local therapies (such as ablation) with systemic targeted therapy to extend survival benefits for patients.

Research Significance and Prospects

From a research perspective, this finding establishes NRG1 fusion as a critical driver in cholangiocarcinoma and validates the clinical value of bispecific antibodies blocking the HER2/HER3 signaling pathway. This has profound implications for drug development, suggesting that future R&D for drugs targeting rare fusion genes should place greater emphasis on transcriptomic-level screening. Simultaneously, the study provides a new dynamic monitoring model for clinical monitoring, using the rapid decline of CA 19-9 for early efficacy assessment. Furthermore, regarding disease modeling, the study underscores the importance of constructing cell line or organoid models containing various fusion partners to more comprehensively evaluate drug sensitivity across different NRG1 fusion subtypes.

 

 

Conclusion

This study, through the eNRGy trial, confirmed the clinical benefits of Zenocutuzumab in patients with advanced NRG1 fusion-positive cholangiocarcinoma, providing not only objective efficacy data but also revealing the key driving role of this target in biliary tract malignancies. From a translational perspective from laboratory to clinic, this achievement marks a new stage of precision targeted therapy for cholangiocarcinoma, particularly emphasizing the irreplaceable role of RNA sequencing in identifying rare driver mutations. For future care systems for related diseases, this study lays a foundational role: comprehensive genomic and transcriptomic testing must be incorporated into routine diagnosis and treatment protocols to ensure that patients carrying NRG1 fusions can receive effective targeted therapy in a timely manner, thereby significantly improving the survival prognosis and quality of life for patients with this refractory tumor.

 

James M Cleary, Christoph Springfeld, Dirk Arnold, Shola Adeyemi, and Alison M Schram. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial. Journal of Clinical Oncology.